To include your compound in the COVID-19 Resource Center, submit it here.

Spiriva Respimat tiotropium: Postmarketing study data

Researchers at Johns Hopkins University and colleagues reported data from a meta-analysis of 6,522 COPD patients from 5 clinical trials showing that Spiriva Respimat tiotropium was associated with a 52%

Read the full 306 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE